For the quarter ending 2026-03-31, RXST made $30,893K in revenue. -$16,004K in net income. Net profit margin of -51.80%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Sales | 30,893 | 32,607 | 30,340 | 33,637 |
| Cost of sales | 7,395 | 7,344 | 6,113 | 8,447 |
| Gross profit | 23,498 | 25,263 | 24,227 | 25,190 |
| Selling, general and administrative | 31,855 | 27,694 | 27,345 | 28,976 |
| Research and development | 9,472 | 8,905 | 9,060 | 10,217 |
| Total operating expenses | 41,327 | 36,599 | 36,405 | 39,193 |
| Loss from operations | -17,829 | -11,336 | -12,178 | -14,003 |
| Interest expense | 3 | 4 | 4 | 5 |
| Interest and other income | 1,954 | 2,194 | 2,376 | 2,254 |
| Loss on extinguishment of term loan | - | 0 | - | - |
| Loss before income taxes | -15,878 | -9,146 | -9,806 | -11,754 |
| Income tax expense | 6 | 6 | 10 | 32 |
| Net loss | -15,884 | -9,152 | -9,816 | -11,786 |
| Unrealized loss on short-term investments | -120 | -11 | 178 | -146 |
| Foreign currency translation gain | 0 | 4 | -1 | 14 |
| Total other comprehensive loss | -120 | -7 | 177 | -132 |
| Comprehensive loss | -16,004 | -9,159 | -9,639 | -11,918 |
| Basic EPS | -0.38 | -0.222 | -0.24 | -0.29 |
| Diluted EPS | -0.38 | -0.222 | -0.24 | -0.29 |
| Basic Average Shares | 41,306,110 | 41,184,305 | 40,965,219 | 40,743,786 |
| Diluted Average Shares | 41,306,110 | 41,184,305 | 40,965,219 | 40,743,786 |
RxSight, Inc. (RXST)
RxSight, Inc. (RXST)